A Phase Ib Study of GC101 in NSCLC

20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.

Trial Details

NCT ID
NCT06473961
Phase
PHASE1
Sponsor
Shanghai Juncell Therapeutics
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Autologous Tumor Infiltrating Lymphocytes
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\. Signed the informed consent form (ICF) and able to comply with the visits and related procedures specified in the protocol;
  • 2\. Aged ≥18 years and ≤70 years, regardless of gender;
  • 3\. Patients with unresectable advanced, recurrent, or metastatic non-small cell lung cancer who are positive for driver genes and have failed afte…
  • 4\. TILs can be isolated from a surgically resectable tumor region: the tissue volume must be \>150mm3, and the lesion has not received local treat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →